Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Avalyn Pharma Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
Avalyn Pharma completed target enrollment in its Phase 2b MIST Trial for AP01 (inhaled Pirfenidone) for progressive pulmonary fibrosis on June 17, 2026, marking a critical milestone that advances the drug toward potential commercialization and validates the inhaled delivery approach for this indication.
Key Takeaways
Phase 2b MIST Trial enrollment completion represents a major development milestone for AP01, positioning the company to move toward data readout and potential Phase 3 planning
AP01 is an inhaled formulation of Pirfenidone, a differentiated delivery approach for a known active pharmaceutical ingredient in pulmonary fibrosis treatment
2 more takeaways